Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23312829 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Conditions: Tuberous Sclerosis Complex (TSC);   Lymphangioleiomyomatosis (LAM)
Interventions: Drug: Everolimus (RAD001);   Drug: Placebo

Indicates status has not been verified in more than two years